Clinical trials using MAF for hospitalized COVID-19 patients
US National Library of Medicine, NIH clinical trial
Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients (SaiseiCovUKR)
Kazakhstan
The clinical trial using MAF capsules has started in Kazakhstan for the patients suffering with coronavirus aftereffects in February 2021.
Ukraine
Update on the clinical trial using MAF for hospitalized COVID-19 patients in Ukraine
Italy
The clinical trial using MAF capsules has started in Italy from November for hospitalised patients with COVID-19.
Ukraine
The clinical trial using MAF capsules has started in Ukraine from the end of October for hospitalised patients with COVID-19.
Rationales of MAF as a therapeutic target for SARS-CoV-2
The fact that around 96% of patients recover from the infection
Potential role of GcMAF
Potential role of GcMAF in suppressing the severity of COVID-19-induced immune responses: Lesson learned from HIV
Free from
Wheat, soy, egg, rice, gluten, starch, sugar (excluding M-Lollies), hormones, antibiotics, preservatives, artificial sweeteners, artificial colours.
Easy to take
We have created 2 types of MAF products to cover many areas such as mouth, gut and skin.
Very unique MAF
We have developed our very own unique MAF (macrophage activating factor) using our patented method. MAF helps boost the immune system by activating macrophages without any side effects.
Produced in GMP Certified factory in Japan
MAF Series products are produced in our Saisei Mirai GMP Certified factory (Certification No. 26518) in Moriguchi, Osaka, certified by the Ministry of Health, Labor and Welfare of Japan.
NEWS
Saisei Pharma plans clinical study of oral MAF in COVID-19 patients
Clinical trial to evaluate oral MAF, macrophage activating factor, in the prevention of the COVID-19 associated cytokine storm and the role of macrophages as a front-line innate immunity defense is announced.
A cytokine storm is a type of severe immune overreaction that could result from the novel coronavirus infection and may contribute to acute respiratory disease which has life-threatening complications in patients with COVID-19.
“Our innate immunity can fight off pathogens without causing inflammation and associated respiratory deterioration.”
We were informed that a company calling themselves “Japan Health” with the websites bio-japan.net and japan-health.net is claiming to be selling our products. This seller is unverified and we have never sold our products to them. Especially our Second Generation GcMAF vials are only sold from Saisei Mirai Clinics in Japan and we do not authorize anyone to re-sell them unless they are registered as a Medical Doctor with us and prescribing them to patients. We recommend ordering GcMAF only from a trusted and reliable source. If you are unsure of the source, please contact us to confirm.
Saisei Mirai Group
We have partnered with 5 domestic clinics in Japan which are based on Saisei Mirai Medical Corporation, bio-venture companies, pharmacies, and universities and medical institutions in Japan and overseas, and have started providing advanced medical care worldwide.
Wholesale Distributors
Momadeus.com
Sweden
shipping within EU countries
MACOTİZM
SPORTİF TESİSLER İŞLETMECİLİĞİ VE DANIŞMANLIK TİC LTD ŞTİ - Turkey
MACMAF
MacMAF is a company owned by macotism
MedInc
Kazakhstan
Uzbekistan, Kyrgyzstan